SITC Guidelines News

last person joined: 2 years ago 

News posts for SITC Cancer Immunotherapy Guidelines

Urothelial Cancer CPG Update v2.4 Now Available

By SITC Scientific Publications News posted 11-01-2024 15:58

  

An update to "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer is now available.

In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. 

Rapid Update v2.4 Summary
The information below provides an overview of update v2.4 to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer" published in Journal for ImmunoTherapy of Cancer (JITC).  

  • The FDA granted accelerated approval of enfortumab vedotin in combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer in December 2023.
  • The FDA granted approval of nivolumab in combination with cisplatin and gemcitabine as first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma in March 2024.
  • Data have been reported indicating similar responses to ICI therapy regardless of FGFR3 mutation status for patients with metastatic urothelial cancer.
  • The FDA granted approval of nogapendekin alfa inbakicept with BCG for adult patients with BCG-unreseponsive NMIBC with carcinoma in situ with or without papillary tumors in April 2024.
  • The mUC immunotherapy treatment algorithm and the NMIBC immunotherapy treatment algorithm have each been updated from the original publication to reflect additional treatment recommendations based on FDA approvals and practice-changing data. 

How to View the Living Guideline Rapid Update

Through the use of an innovative technology, rapid updates are swiftly integrated into our existing published guidelines in a clear and concise manner. An overlay system highlights affected content and provides new text reflecting the updated Expert Panel guidance as well as important supporting information, data, and references, as applicable. These rapid updates show the progression of the changes by using a version numbering system that accompanies each new posted update.

  • View Update v2.4 as an overlay to the original publication in JITC

For More Information

  •        SITC Urothelial Cancer CPG – Overview of all available updates and companion guideline educational offerings for this guideline
  • SITC Guidelines Program – Listing of all published guidelines in the SITC CPG catalogue and more about the SITC Living Guidelines rapid updates
    • Follow us on social media - #SITCGuidelines on "X" and LinkedIn
    • Questions - Contact a member of the SITC guidelines developments staff at scientificresources@sitcancer.org 

      Permalink